↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
KKR takes Integer private at **$5.7B** without competing bids, securing a sole-source medical device supplier with **61% gross margins** and multiyear customer contracts.
$5.7 billion
acquisition by a KKR-managed fund affiliate
2.8x trailing revenue
based on the company's most recent
$2.04 billion
in annual sales
$119.50 per share
representing a
Integer Holdings shareholders voted overwhelmingly to approve a $5.7 billion acquisition by a KKR-managed fund affiliate, clearing the final shareholder hurdle for the medical device manufacturer's exit from public markets. The single-session approval came without material opposition, indicating institutional holders accepted the premium without extracting a competing bid.
The transaction values Integer at roughly 2.8x trailing revenue based on the company's most recent $2.04 billion in annual sales. KKR structured the deal as an all-cash take-private at $119.50 per share, representing a 32% premium to Integer's undisturbed trading price before acquisition rumors surfaced in late 2024. The vote concludes a four-month process that began with exclusivity negotiations in November and moved to definitive agreement by mid-December. No rival bidders emerged during the go-shop period, despite Integer's position as a sole-source supplier for cardiac rhythm management and neuromodulation components used by Medtronic, Abbott, and Boston Scientific.
The shareholder approval matters because Integer operates with 61% gross margins and carries relationships that require 18-24 month qualification cycles for new entrants to replicate. KKR inherits a business with $847 million in contracted backlog and manufacturing facilities that hold FDA registrations across five continents. The private equity buyer also assumes $1.2 billion in net debt, bringing total enterprise value to roughly $6.9 billion. Three of Integer's top five customers have multiyear supply agreements extending through 2027, providing revenue visibility that supports leveraged returns even in a higher-rate environment.
The deal structure gives KKR control of a component supplier at a moment when medical device OEMs face pressure to secure supply chains outside China. Integer's Thailand and Mexico manufacturing footprint positions the company as a beneficiary of supply diversification mandates that Medtronic and Abbott codified in late 2023. KKR's industrial team has previously taken Capsugel and Envision Healthcare private, executing operational improvements before either reselling or taking companies public at higher multiples. Integer's margin profile and customer concentration create a narrower playbook: incremental capacity expansion in existing facilities rather than transformational M&A.
Operators should monitor two follow-on events. First, Integer's management retention packages typically vest over 36 months under KKR ownership, with CEO Joe Dziedzic's contract extending through December 2027. Any early departures would signal integration friction or strategic pivots. Second, Integer's largest customers will renegotiate pricing during the next annual review cycle in Q3 2025, testing whether private ownership changes the company's willingness to accept low-single-digit annual price increases. A shift toward mid-single-digit increases would confirm KKR's thesis that Integer undermonetized its sole-source position while public.
The transaction closes in Q2 2025 pending HSR clearance, which carries minimal antitrust risk given Integer's sub-4% share of the global medical device contract manufacturing market.
Branded by POPS4 · proof in 60 seconds
For the principal
Monitor Integer's Thailand/Mexico capacity for supply chain diversification opportunities; management retention through 2027 signals operational continuity under private ownership.
For the operator
Track Integer's Q3 2025 customer pricing negotiations for signals on whether KKR pushes margin expansion; any Dziedzic departure accelerates strategic pivot timeline.
For the house
Named accounts exploring medtech component exposure should wait for post-close operational review; better entry at refinancing event in 24-30 months than pre-close premium.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.